



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Clinical characteristics of Neuromyelitis optica spectrum disease (NMOSD) and factors affecting treatment response

Thesis

*Submitted for Partial Fulfillment of master's degree
in Neuropsychiatry*

By

Monica Samir Noaman Abdel-Messih

MB, BCh Ain Shams University

Under Supervision of

Prof. Dr. Azza Abdel Nasser abdel aziz

*Professor of Neurology
Faculty of Medicine - Ain Shams University*

Prof. Dr. Dina Mohamed Abdel Gawad Zamzam

*Professor of Neurology
Faculty of Medicine - Ain Shams University*

Assistant Prof. Sherien Mohamed Farag

*Assistant professor of Neurology
Faculty of Medicine - Ain Shams University*

**Faculty of Medicine
Ain Shams University
2021**



الخصائص الاكلينيكية لاضطرابات التهاب النخاع والعصب البصري والعوامل التي تؤثر على الاستجابة للعلاج

رسالة

**توطئة للحصول على درجة الماجستير في طب المخ والأعصاب
والطب النفسي
مقدمة من**

**الطبيبة / مونيكا سمير نعمان عبد المسيح
بكالوريوس الطب والجراحة - جامعة عين شمس**

تحت إشراف

أد/ عزة عبد الناصر عبد العزيز

أستاذ طب المخ والأعصاب
كلية الطب- جامعة عين شمس

أد/ دينا محمد عبد الجواد زمزم

أستاذ طب المخ والأعصاب
كلية الطب- جامعة عين شمس

أم د/ شيرين محمد فرج

أستاذ مساعد طب المخ والأعصاب
كلية الطب- جامعة عين شمس

كلية الطب

جامعة عين شمس

٢٠٢١



Acknowledgement

*First and foremost, thanks to **ALLAH**, the Most Merciful.*

*I wish to express my deep appreciation and sincere gratitude to **Prof. Dr. Azza Abdel Nasser abdel aziz**, Professor of Neurology, Ain Shams University, for her close supervision, valuable instructions, continuous help, patience, advice and guidance. She has generously devoted much of her time and effort for planning and supervision of this study. It was a great honor to me to work under her direct supervision.*

*I wish to express my great thanks and gratitude to **Prof. Dr. Dina Mohamed Abdel Gawad Zamzam**, Professor of Neurology, Ain Shams University, for her kind supervision, indispensable advice, and great help in this work.*

*I wish to express my great thanks and gratitude to **Dr. Sherien Mohamed Farag**, Lecturer of Neurology, Ain Shams University, for her kind supervision, indispensable advice, and great help in this work.*

Last and not least, I want to thank all my family, my colleagues, for their valuable help and support.

Finally, I would present all my appreciations to my patients without them, this work could not have been completed.

CONTENTS

Title	Page
• List of Abbreviations	I
• List of Table	IV
• List of Figures.....	VI
• Introduction	1
• Aim of the work	5
• Review of literature.....	
Chapter (1): NMOSD epidemiology and pathogenesis.....	6
Chapter (2): NMOSD clinical picture and diagnosis	15
Chapter (3): NMOSD treatment.....	29
Chapter (4): CNS Demyelinating Disorders and differential diagnosis for NMOSD	50
• Patients and methods	86
• Results	90
• Discussion.....	123
• Conclusions	139
• Recommendations	141
• Summary	143
• References	151
• الملخص العربي	-

LIST OF ABBREVIATIONS

Abb.	Full term
ADCC	: Antibody-Dependent Cellular Cytotoxicity
ADEM	: Acute Disseminated Encephalo-Myelitis
AHL	: Acute Haemorrhagic Leucoencephalitis
ANHE	: Acute Necrotizing Hemorrhagic Encephalomyelitis,
anti-TNF α	: Anti-tumor necrosis factor-alpha Anti-tumor necrosis factor-alpha
APL	: Anti-phospholipid
APS	: Area Postrema Syndrome
AQP	: Aquaporin
AQP4 IgG	: Aquaporin-4 Immunoglobulin G
AQP4-Ab	: Aquaporin 4 antibody
ARR	: Annualized Relapse Rate
ATG	: Anti-Thymocyte Globulin
AZT	: Azathioprine
BBB	: Blood-Brain Barrier
BBB	: Blood Brain Barrier
BD	: Behcet's Disease
CDC	: Complement-Dependent Cytotoxicity
CDR	: Complementarity-Determining Region
CIS	: Clinical Isolated Syndrome
CNS	: Central Nervous System
CNS	: Central Nervous System
CPM	: Central Pontine Myelinolysis
CR	: Complete Response
CRP	: C-Reactive Protein
CSF	: Cerebrospinal fluid
CVST	: Cerebral Venous Sinus Thrombosis
DMT	: Disease Modifying Therapy
EDSS	: Expanded Disability Status Scale
ELISA	: Enzyme-linked Immunosorbent Assay
EMA	: European Medicines Agency
EPM	: Extra-Pontine Myelinolysis
ESR	: Erythrocyte Sedimentation Rate
FDA	: Food and Drug Administration
FDG	: 2-18F-fluoro-2-deoxyglucose
FLAIR	: fluid-attenuated inversion recovery
GA	: Glatiramer Acetate
GFAP	: Glial Fibrillary Acidic Protein

List of Abbreviations

Abb.	Full term
HELLP	: Hemolysis, Elevated Liver enzymes and Low Platelet levels
HIV	: Human Immunodeficiency Virus
HLA	: Human Leukocyte Antigen
HSCT	: Hematological Stem Cell Transplantation
ICAM1	: Intracellular Adhesion Molecule 1
ICBD	: The International Criteria for Behcet's Disease
ICU	: Intensive Care Unit
IFNβ	: Interferon β
IgG	: Immunoglobulin G
IIDDs	: Idiopathic Inflammatory Demyelinating Diseases
IIF	: Indirect Immunofluorescence
IL	: Interleukin
IL-6	: Interleukin-6
IM	: Intramuscular
IPMSSG	: The International Pediatric Multiple Sclerosis Study Group
IPND	: International Panel for NMO Diagnosis
IPND	: International Panel for Neuromyelitis optica Diagnosis
ISG	: International Study Group for Behcet's Disease
ITM	: Idiopathic Transverse Myelitis
IVIg	: Intravenous Immunoglobulins
IVMP	: Intravenous Methylprednisolone
LETM	: Longitudinally extensive transverse myelitis
LETM	: Longitudinal Extensive Transverse Myelitis
mAb	: monoclonal antibody
MAC	: Membrane Attack Complex
MM	: Mycophenolate Mofetil
MOG	: Myelin Oligodendrocytes Glycoprotein
MOGAD	: Myelin Oligodendrocyte Glycoprotein antibody disorder
MRI	: Magnetic Resonance Imaging
MRI	: Magnetic Resonance Imaging
MS	: Multiple Sclerosis
MS	: Multiple Sclerosis
NBD	: Neuro-Behcet's Disease
NMO	: Neuromyelitis Optica
NMOSD	: Neuromyelitis Optica spectrum disease
NPSLE	: Neuropsychiatric Systemic lupus erythematosus
ON	: Optic Neuritis

List of Abbreviations

Abb.	Full term
ON	: Optic Neuritis
ONTT	: Optic Neuritis Treatment Trial
OSMS	: Optico-Spinal form of Multiple Sclerosis
PET	: Positron Emission Tomography
PLEX	: Plasma Exchange
PML	: Progressive Multifocal Leukoencephalopathy
PNS	: Peripheral Nervous System
PPMS	: Primary Progressive Multiple Sclerosis
RA	: Rheumatoid Arthritis
RMS	: Relapsing Multiple sclerosis
RRMS	: Relapsing Remittent Multiple sclerosis
SC	: Subcutaneous
SD	: Standard deviation
SLE	: Systemic lupus erythematosus
SPMS	: Secondary Progressive Multiple Sclerosis
Th1	: T-helper 1
Th17	: T Helper 17
Th2	: T-helper 2
TM	: Transverse Myelitis
TM	: Transverse myelitis
TNF	: Tumor Necrosis Factor
UK	: United Kingdom
URTI	: Upper Respiratory Tract Infection
US	: United States
UTI	: Urinary Tract Infection
VCAM-1	: Vascular Cell Adhesion Molecule 1
VEGF-A	: Vascular Endothelial Growth Factor A
VEP	: Visual Evoked Potential
WHO	: World Health Organization

LIST OF TABLE

Table No	Subjects	Page
Table (1):	The International Panel for NMO Diagnosis (IPND):	26
Table (2):	Neuroimaging characteristics of NMOSD.....	27
Table (3):	Red flags of NMOSD	28
Table (4):	Characteristics of the most common maintenance treatments for NMOSD.....	49
Table (5):	Diagnostic Criteria for Multiple Sclerosis	54
Table (6):	Approved Disease-Modifying Therapies for MS	58
Table (7):	The International Pediatric Multiple Sclerosis Study Group (IPMSSG) Criteria for acute disseminated encephalomyelitis (ADEM) and relapsing disorders following ADEM:.....	63
Table (8):	Proposed diagnostic criteria for idiopathic acute transverse myelitis:	69
Table (9):	Demographic data of the studied group.....	92
Table (10):	Core clinical characteristics of the studied group:.....	95
Table (11):	Duration of illness of the studied group:	96
Table (12):	Duration of illness of the studied group:	97
Table (13):	Radiological characteristics of the studied group:.....	99
Table (14):	Aquaporin status and VEP of the studied group:.....	100
Table (15):	Treatment of attacks and preventive immunotherapy the studied group	103
Table (16):	Difference between EDSS mean score before and after medication in the studied group	106
Table (17):	Relation between EDSS, treatment during attacks and DMD in the studied group:	107
Table (18):	Relation between EDSS and demographic data of the studied group.....	109

List of Table

Table No	Subjects	Page
Table (19):	Relation between EDSS and clinical characteristics of the studied group:	111
Table (20):	Relation between EDSS and MRI lesions of the studied group:	112
Table (21):	Relation between EDSS and VEP of the studied group:	113
Table (22):	Correlation between EDSS, clinical data and MRI total lesions in the studied group:	114
Table (23):	Relation between Aquaporin status and demographic data in the studied group:	115
Table (24):	Relation between Aquaporin status and clinical characteristics of the studied group:	116
Table (25):	Relation between Aquaporin status and MRI lesions of the studied group:	117
Table (26):	Relation between Aquaporin status, Age, Number of relapses and MRI lesions in the studied group:	118
Table (27):	Relation between Aquaporin status and EDSS in the studied group:	119
Table (28):	Relation between DMD and number or relapse in the past 2 years in the study group:	122

LIST OF FIGURES

Figure No	Subjects	Page
Figure (1):	Optic affection:	22
Figure (2):	Spinal Cord affection:	22
Figure (3):	Spinal cord affection.....	23
Figure (4):	Cerebral affection	24
Figure (5):	Escalation therapy in MS patients	57
Figure (6):	A therapeutic algorithm for DMT use in MS	60
Figure (7):	MRI finding in Neuro Behcet disease..	78
Figure (8):	T2W sagittal and axial cervical MRI images, showed long segment of abnormal intramedullary bright T2 signal.....	79
Figure (9):	Gender of the studied group	93
Figure (10):	Past history of the studied group	93
Figure (11):	Family history of consanguinity of the studied group	94
Figure (12):	Family history of similar condition of the studied group	94
Figure (13):	Type of relapses in the studied group	97
Figure (14):	Aquaporin status of the studied group	101
Figure (15):	Visual evoked potential of the studied group	101
Figure (16):	Treatment during attack in the studied group	104
Figure (17):	Current DMD of the studied group.....	104
Figure (18):	EDSS before and after medication in the studied group	106
Figure (19):	Relation between EDSS and treatment during attack in the studied group	108
Figure (20):	Relation between EDSS and DMD in the studied group	108
Figure (21):	Relation between EDSS after medication and Aquaporin status in the studied group	120

✍ List of Figures

Figure No	Subjects	Page
Figure (22):	Relation between EDSS after medication and Aquaporin status in the studied group	120
Figure (23):	Relation between DMD and number or relapse in the past 2 years in the studied group.....	122

ABSTRACT

Background: Neuromyelitis Optica (NMO) previously known as Devic's syndrome is an autoimmune, inflammatory and demyelinating disorder of the central nervous system with predominant affection of the optic nerves and spinal cord. The global incidence and prevalence of NMO is incompletely characterized. To be more specific, it is unclear whether disease severity, frequency, clinical picture, and gender predominance vary between geographical regions. It's really challenging to obtain epidemiological and demographic data for a disorder like NMO, as it's relatively uncommon.

Aim of the Work: Study the demographic data of the patients affected with NMOSD attending ASU neurology MS unit, Document patient's response to treatment. and to estimate the incidence rate of NMOSD, according to the new international consensus NMO Diagnosis criteria.

Patients and Methods:

Patient attending ASU MS unit, during one year study time, Age: 18 to 65 years old, with Diagnosis of NMOSD according to the International consensus on NMOSD.

Results: 50 NMO patients were enrolled in this study, Mean age of NMO patients was 33.140 ± 9.136 , ranging from 20 to 59 years, 39 were females representing 78% of the study group while 11 were males representing 22%. EDSS showed significant relation with treatment during acute attack and receiving DMD as a preventive therapy with p-value 0.052 and 0.024 respectively.

Conclusion: Since the landmark discovery of AQP4-IgG, the clinical spectrum of NMO has expanded, and non- optico-spinal clinical manifestations are recognized, accordingly rational targeted treatments have been identified that are now being delivered to patient care.

Keywords: NMO, Aquaporin, Treatment response, Rituximab, Optic neuritis, Myelitis.